January 2026

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Felix Group Holdings reported a robust 47% increase in total annual recurring revenue for Q2 FY26, driven by the strategic acquisition of Nexvia and expanding enterprise contracts. The company is advancing AI-powered platform enhancements and navigating key leadership transitions.

Celsius Resources has delivered a robust Definitive Feasibility Study for its Maalinao-Caigutan-Biyog Copper-Gold Project, confirming a 35-year mine life and strong economic returns. The company is actively progressing funding arrangements amid growing investor interest.

Nimy Resources has announced a maiden JORC Inferred Resource for high-grade gallium and rare earth elements at its Mons Project in Western Australia, marking a significant step towards becoming a key supplier in critical minerals.

Pilot Energy has made significant strides in Q4 2025 with the launch of a modular data centre joint venture, progress on a hybrid solar and battery project, and advancement of offshore gas exploration partnerships, supported by substantial new financing.

Blue Energy Limited reports steady progress on its Sapphire gas project and awaits key government decisions on additional resource areas, positioning itself strongly in Queensland's evolving energy landscape.

Golden Horse Minerals reports multiple shallow, high-grade gold intersections at Golden Valley and significant deep drilling success at Southern Cross, backed by a $35 million capital raise to fuel 2026 growth.

Vita Resources NL, formerly Bastion Minerals, has advanced its Canadian and Australian projects with new exploration agreements and acquisitions, supported by a recent capital raise. The company is gearing up for significant exploration activities in 2026 under its refreshed corporate identity.

Holista Colltech has reported a positive operating cash flow for the December quarter, driven by disciplined cost management and a successful capital raise, despite softer sales and ongoing legal disputes.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Cullen Resources Limited has outlined an active exploration agenda for early 2026, advancing drilling programs across its gold and base metal projects in Western Australia and Finland while maintaining a stable financial footing.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Manuka Resources has released an updated 10-year Pre-Feasibility Study for its Cobar Basin projects, revealing a substantial uplift in project economics and a clear path to production by mid-2026.

Power Minerals has commenced a significant 10,000m reverse circulation drilling program at its Santa Anna Project in Brazil, aiming to expand and deepen the footprint of high-grade niobium and rare earth elements mineralisation. Results are anticipated by late March 2026.

Emerald Resources NL reported solid December quarter gold production from its Okvau Gold Mine and significant resource upgrades at its Dingo Range and Memot projects, underpinning its growth trajectory.

Magmatic Resources has reported encouraging gold assay results from its Weebo Gold Project and advanced drilling at its Myall Copper-Gold JV, alongside securing a $3 million placement led by FMG Resources.

MRG Metals has expanded its rare earth portfolio through the acquisition of the high-grade Garies Rare Earth Project in South Africa, while also progressing key projects in Mozambique, signalling a diversified growth strategy in critical minerals.

Nagambie Resources and Alkane Resources have entered a binding agreement for a joint venture that could see Alkane invest up to $27.5 million to earn an 80% stake in Nagambie's key mining tenements, leveraging Alkane’s existing processing infrastructure to accelerate production.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Alpha HPA Limited has successfully raised A$225 million through a fully underwritten equity placement, bolstered by strong institutional support, to fund the next phase of its high purity alumina project. This capital injection, combined with existing cash and government funding, positions the company to advance its Stage 2 construction and expand Stage 1 capacity.

Evion Group gains momentum as the US-Africa Strategic Infrastructure and Investment Working Group fosters trade, Madagascar accelerates mining permits, and Indian graphite operations deliver strong sales.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Beetaloo Energy has secured key regulatory approvals and approved the Final Investment Decision for its Carpentaria Pilot Project, setting the stage for first gas sales from EP187 in late 2026.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.